Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study by �궓沅곴린
© 2003 Medical Council on Alcohol
135
INTRODUCTION
Alcohol dependence is one of the most important health issues
throughout the world. Its prognosis is known to be poor. Korea
is no exception in this respect, and, for these reasons, acam-
prosate has drawn the attention of many clinical investigators.
Acamprosate (calcium acetylhomotaurinate) has been
postulated to be a helpful adjunct to conventional out-patient
treatment after detoxification for the treatment of alcohol
dependence. Most European clinical trials of acamprosate in
detoxified alcoholics have demonstrated a statistically signifi-
cant lengthening of time to first drink, a reduction in drinking
days, and an increase in the percentage attaining complete
abstinence (Lhuintre et al., 1985; Pelc et al., 1992, 1997;
Ladewig et al., 1993; Paille et al., 1995; Sass et al., 1996;
Whitworth et al., 1996; Barrias et al., 1997; Geerlings et al.,
1997; Poldrugo, 1997; Tempesta et al., 2000). However, these
findings have not yet been replicated outside Europe.
It is generally believed that Asians have a lower rate of
alcoholism, because of the flushing reaction to ethanol due 
to a reduced level of aldehyde dehydrogenase (Goedde et al.,
1984). However, the lifetime prevalence of alcohol dependence
in Korea by Diagnostic Interview Schedule (DIS)/DSM-III
was found to be 10.3%, which is higher than was found using
the same method in western countries as well as in other Asian
countries (Helzer et al., 1990; Namkoong et al., 1990). In 
addition, Koreans have their own unique concept of alcoholism
and drinking style, compared with other Asian peoples.
Given the emerging role of genetic and cultural issues in
drug treatment, it was considered important to evaluate the
efficacy and safety of acamprosate for alcohol dependence in
different ethnic groups, such as in this Korean sample.
PATIENTS AND METHODS
This study was a multi-centre, randomized, double-blind,
placebo-controlled clinical trial undertaken to evaluate the
efficacy and safety of acamprosate for the treatment of Korean
alcohol-dependent patients. Following baseline assessment,
142 alcohol-dependent patients were randomized to receive
either acamprosate or a placebo over a period of 8 weeks. This
treatment was combined with an out-patient psychosocial
treatment programme.
Subjects
Subjects were recruited through newspaper advertisements
or as patients seeking treatment at the out-patient clinics of
seven university general hospitals and five psychiatric hospitals,
which had an alcohol treatment programme.
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Abstract — Aims: A multi-centre, randomized, double-blind, placebo-controlled trial was conducted to evaluate the efficacy and the
safety of acamprosate over 8 weeks in Korean alcohol-dependent patients. Methods: One hundred and forty-two alcohol-dependent
patients in 12 centres were randomized to 8 weeks treatment with either acamprosate (n = 72) or a placebo (n = 70) in combination
with out-patient psychosocial intervention. They were predominantly male (95.8%), with a mean age of 44.3 ± 8.3 years; 76.1% were
married; 59.9% were employed; 58.5% had received previous alcoholism treatment (previous mean number of admissions in
alcoholism in-patient programmes 4.6 ± 6.9). At visits to the clinic (weekly for 4 weeks, then biweekly for 4 weeks), a record was
made of alcohol use (Time-Line Follow-Back), alcohol craving using a Korean version of the Obsessive Compulsive Drinking Scale and
a visual analogue scale, and adverse events. Serum aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase
(GGT), blood urea nitrogen and creatinine levels were measured on weeks 0, 2, 4 and 8. Results: In the acamprosate group (A), 71.4%
had had alcohol within the 2 days prior to starting medication, against 65.2% of patients in the placebo group (P); (P > 0.05). One
hundred and one subjects (71.1%) completed 8-weeks of treatment (A, 73.6%; P, 68.6%; P > 0.05). During the 8-week treatment period,
37, (A) (n = 72) and 32% (P) (n = 70) achieved continuous abstinence (P > 0.05), and 40, (A) and 39% (P) remained without relapse 
(P > 0.05) (defined as a day when a man consumed five or more drinks or a woman four or more drinks). The percentage of days
abstinent during the 8-week treatment period was 81.2, (A) and 78.5% (P) (P > 0.05), and the percentage of days without heavy
drinking 86.1 (A) and 84.9% (P) (P > 0.05). The mean amount drunk per drinking occasion was 7.2, (A) and 8.6 standard drinks 
(P) (P > 0.05). No statistically significant differences in changes in the serum GGT level or craving scores from baseline to the end-
point of treatment were found between the two groups. Recency of drinking prior to commencing study drug predicted percentage of
days abstinent in the first 2 weeks on treatment; however, when ANOVAs were conducted using treatment outcomes as a dependent
variable, medication condition as an independent variable and the period of abstinence prior to treatment as a covariate, a significant
effect of medication condition was still not seen. Conclusions: Acamprosate was ineffective in reducing drinking in this Korean
sample. The result differs from that of most European acamprosate trials. This might be explained by our sample’s relatively severe
alcohol dependence, and low social support, or the fact that many patients were still drinking near to their first medication. The
variability of the psychosocial support, ethnicity (which might also affect acamprosate pharmacokinetics) and the Korean drinking
style, which differs from that of Europeans, might have contributed to our negative result.
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Yondong, PO Box 1277, Seoul, South Korea.
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on July 20, 2014
http://alcalc.oxfordjournals.org/
D
ow
nloaded from
 
An initial screening examination and assessment was
conducted within 4 weeks of the end of detoxification. Detoxi-
fication may have been carried out on an in-patient or out-
patient basis for patients who were clinically assessed to be 
in need of detoxification. Patients had to be free of benzo-
diazepines and were instructed not to drink alcohol between
the initial screening and randomization session (week 0). Patients
who had a positive breathalyser result on day 0 were required
to return on the next day. Individuals from 21 to 65 years of
age were eligible to participate if they: (1) met the DSM-IV
criteria (American Psychiatric Association, 1994) for alcohol
dependence; (2) were able to read and write Korean; (3) had a
stable residence and a telephone. Criteria for exclusion included:
(1) current misuse or dependence on a substance other than alcohol
or nicotine; (2) acute major psychiatric illness or psychotic
illness; (3) liver cirrhosis or renal problem (serum creatinine
> 1.2 mg/dl); (4) unstable medical condition; (5) current use of
disulfiram or regular use of psychotropic medication; (6) previous
treatment with acamprosate; (7) among women, pregnancy,
nursing or refusal to use a reliable form of birth control.
Written informed consent was obtained at the initial screen-
ing session. The protocol was approved by the Internal Review
Board of each centre and the National Food and Drug Admin-
istration, and was conducted in accordance with the amended
Declaration of Helsinki (World Medical Association, 1997).
An unspecified number of subjects were approached for
initial screening by investigators in each centre. Of a total 
of 153 patients meeting initial eligibility criteria, 11 potential
participants declined to participate or dropped out prior to
randomization for the following reasons: they were unable to
abstain for just 1 day (n = 2), lost to follow-up (n = 4), refused
treatment (n = 3), and refused to take medication (n = 2)
between assessment and randomization. Enrolment in the
study took place only after an examination by a psychiatrist, a
physical examination and after blood and urine laboratory
tests had been completed.
A total of 142 subjects were randomized with respect to 
the medication according to age, sex and body weight, and
actually attended the first treatment session at which study
medications were dispensed. Seventy-two of the subjects were
randomized to acamprosate, and 70 to a placebo treatment.
Rates of treatment enrolment and study completion are
displayed in Fig. 1.
Treatments
After the initial screening session, eligible patients were
randomized to receive acamprosate or placebo by the principal
investigator (K.N.), using a computer-generated schedule.
Investigators remained blind to the medication assignment.
Patients visited the clinic weekly for the first 4 weeks, and
biweekly for the second 4 weeks. At each visit, 1332 mg/day
(<60 kg body weight) or 1998 mg/day (‡ 60 kg) of acampro-
sate or equivalent numbers of identically presented placebo
tablets were dispensed, and the subjects also underwent the
clinic’s usual psychosocial treatment, which included medical
counselling, brief psychotherapy, and encouragement to attend
AA sessions or cognitive behavioural therapy.
Assessments
At intake, a record was made of sociodemographic charac-
teristics, physical examination, laboratory testing (liver and
renal function) and psychiatric status. Drinking behaviour for
the preceding 4 weeks prior was assessed using Time-Line
Follow-Back (TLFB) (Sobell and Sobell, 1992). Diagnoses of
substance use disorders and other psychiatric disorders were
obtained from a psychiatrist’s clinical interview, according to
DSM-IV criteria (American Psychiatric Association, 1994).
At every visit, alcohol use from the time of the previous
visit was recorded using TLFB. Breathalyser tests were admin-
istered at all assessment sessions. Alcohol craving was meas-
ured using a Korean version of the Obsessive Compulsive
Drinking Scale (OCDS) (Anton et al., 1995, 1996) and a
visual analogue scale (VAS). Serum total bilirubin, aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
gamma-glutamyltransferase (GGT), blood urea nitrogen
(BUN) and creatinine levels were measured at weeks 0, 2, 4
and 8. Finally, adverse events were monitored at each visit using
the SAFTEE–GI (Levine and Schooler, 1986). To determine
medication compliance, returned tablets were counted.
Statistical analyses
Following the intention-to-treat (ITT) principle, any random-
ized patient who took at least one dose of study medication
was entered into the analysis. Primary outcome variables and
statistical methods were as follows: (1) length of time to the
first drink and the length of time to the first relapse. Time to
136 K. NAMKOONG et al.
Fig. 1. Patient enrolment and discontinuation.
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the first relapse was defined as days until the first day of heavy
drinking, defined as five or more drinks in a day (males) or
four or more drinks (females). Kaplan–Meier survival analysis
was used to examine differences in these between the acam-
prosate and the placebo groups. (2) Per cent days abstinent,
per cent days without heavy drinking, and mean consumption per
drinking occasion was summarized for the entire study period.
For these measures, differences between the two medication
groups were examined using the Student’s t-test.
Secondary outcome variables were the following: (1) per
cent days abstinent, per cent days without heavy drinking, 
and mean drinking amount per drinking occasion, summarized
over each 4-week period. Longitudinal outcomes with repeated
measures were analysed by random coefficient regression
analyses using the PROC MIXED procedure of Statistical
Analysis System (SAS). Summary scores during the baseline
4 weeks were treated as time point 0 for the model. Medication
by time interactions were tested on a period-by-period basis to
evaluate how they changed with time. Because the distribution
of scores of the number of drinks per drinking day was highly
skewed, these scores were square-root-transformed prior to
analysis. (2) Changes in a measure of craving for alcohol pro-
vided by the OCDS and VAS. (3) Changes in the GGT level
from baseline to the end-point carried forward. Analysis of
variance (ANOVA) with repeated measure was used to exam-
ine differences between the groups.
Relationship between the period of abstinence prior to
treatment and the percentage of days abstinent during the
treatment period was analysed by Pearson’s correlation.
RESULTS
Sample characteristics
The sample was primarily male (95.8%), married (76.1%),
well educated (high school graduate or beyond 69.0%) and
employed (59.9%), and of mean ± SD age 44.3 ± 8.3 years.
More than half of the subjects (58.5%) had received previous
treatment for alcoholism. Their mean number of previous
admissions to alcoholism in-patient programmes was 4.6 ± 6.9.
Their mean ± SD baseline score on the Alcohol Dependence
Scale (ADS) (Skinner and Horn, 1984) was 21.5 ± 8.4. Sixty-
eight per cent of the sample had a drink within the previous 
2 days of starting medication [71.4% of the acamprosate group
(A), 65.2% of the placebo group (P); P > 0.05]. They drank
for an average of 52.7 ± 32.7% of the 28-day pre-treatment base-
line period, and consumed an average of 18.0 ± 11.7 standard
drinks per drinking occasion.
The groups formed by randomization did not differ in terms
of demographic, clinical characteristics or the number of days
abstinent from alcohol before treatment (Table 1).
Treatment exposure
One-hundred and one patients (71.1%) completed the 8-week
treatment period. Attrition was equal in both treatment groups:
19 patients (26.4%) on acamprosate and 22 patients (31.4%)
on placebo. The reasons for premature termination are shown
in Fig. 1.
There were no significant differences between the two groups
with respect to medication compliance [percentage of tablets
patient took: 80.5 ± 30.8% (A), 74.3 ± 32.2% (P); t = 1.135,
df = 129, P = 0.259] or in the number of psychosocial treat-
ment sessions attended [6.19 ± 3.10 (A), 6.17 ± 2.86 (P); 
t = 0.046, df = 140, P = 0.963].
Treatment effectiveness
Continuous abstinence and relapse rates in survival
analysis. Figures 2 and 3 illustrate the cumulative rates of ab-
stinence and time to the first relapse according to medication
group. The median time to the first drink was 14 and 8 days
for the acamprosate and placebo groups, respectively, and the
corresponding median time to the first relapse was 21 (A) and
22 days (P). The proportion of patients achieving continuous
abstinence over the entire 8-week treatment period was 37% 
(A) and 32% (P); 40% (A) and 39% (P) maintained abstinence
or drank but without meeting the criteria for relapse to heavy
drinking. There were no significant differences in the time to
the first drink (log rank statistics = 0.36, df = 1, P = 0.55), or in
the time to relapse (log rank statistics = 0.02, df = 1, P = 0.90),
between the two groups.
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Table 1. Demographic characteristics and drinking behaviours over the 4 weeks of baseline
Parameter (numbers or means) Acamprosate (n = 72) Placebo (n = 70)
Sex (% male) 69 (95.8) 67 (95.7)
Age (years) (mean ± SD) 44.7 ± 8.7 43.9 ± 8.0
Marital status (% married) 56 (77.8) 52 (74.3)
Educational level (years) (mean ± SD) 12.3 ± 3.8 12.2 ± 3.7
Employment (% employed) 45 (62.5) 40 (57.1)
Family history of alcoholism (% positive) 33 (45.8) 34 (48.6)
Previous episode of alcohol treatment (%) 43 (59.7) 40 (57.1)
In-patient detoxification before study (%) 27 (37.5) 29 (41.4)
Interval between last drink and the first medication
Mean ± SD (days) 3.9 ± 6.6 3.8 ± 6.2
Range (days) 0–27 0–26
Patients who had a drink within the previous 2 days of starting medication 50 (71.4) 45 (65.2)
% Days drinking over 4 weeks of baseline (mean ± SD) 51.2 ± 32.4 54.1 ± 33.1
% Days heavy drinking over 4 weeks of baseline (mean ± SD) 47.6 ± 32.9 48.1 ± 31.9
Mean drinks per drinking occasion over 4 weeks of baseline (± SD) 18.4 ± 12.5 17.5 ± 10.9
Total score of Alcohol Dependence Scale (mean ± SD) 20.4 ± 8.2 22.7 ± 8.6
There were no significant differences in all variables.
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Drinking frequency and amount during the study period. In
the ITT analysis for all subjects, acamprosate-treated subjects
abstained for an average of 81.2% of the entire study days,
whereas placebo-treated subjects abstained for 78.5% of the
study days, and acamprosate-treated subjects did not drink
heavily for an average of 86.1% of the entire study days,
whereas placebo-treated subjects did not drink heavily for 84.9%
of the study days. These differences, though slightly favouring
the acamprosate group, were not statistically significant 
(t = 0.60, df = 129, P = 0.55; t = 0.30, df = 129, P = 0.77). Sub-
jects receiving acamprosate drank a mean of 7.2 standard drinks
per drinking occasion during the entire study period, whereas
subjects receiving the placebo drank a mean of 8.6 standard
drinks per drinking occasion, but this difference was not stat-
istically significant (t = 0.82, df = 129, P = 0.41) (Table 2).
Change of drinking frequency and amount with time.
Although both groups demonstrated higher levels of abstinent
days and days without heavy drinking, and a lower number of
drinks per drinking occasion, than during the pre-treatment
period (Fig. 4), the random effects regression model did 
not reveal any significant medication by time interaction
[F(1,102) = 0.00, P = 0.96; F(1,102) = 0.02, P = 0.90;
F(1,102) = 0.48, P = 0.49, respectively].
Measure of alcohol craving and serum GGT. Alcohol
craving measured by OCDS and VAS (Table 2) at baseline
decreased by the end-point in both groups [OCDS, 19.9 ± 9.6
to 11.5 ± 11.1 (A), 22.2 ± 11.7 to 14.9 ± 11.2 (P); VAS, 
3.2 ± 3.7 to 2.0 ± 2.6 (A), 3.8 ± 4.0 to 2.7 ± 3.1 (P)], but no sig-
nificant medication by time interaction [OCDS, F(1) = 0.316,
P = 0.575; VAS, F(1) = 0.084, P = 0.773] was observed by
analysis of variance with repeated measures. The serum 
GGT level also decreased [87.2 ± 119.5 to 74.0 ± 126.3 (A),
141.4 ± 231.2 to 98.3 ± 157.6 (P)] without producing a
significant medication by time interaction [F(1) = 2.714, 
P = 0.102] (Table 2).
Relationship between the period of abstinence prior to
treatment and the percentage of days abstinent during
treatment period
The interval between last drinking and the beginning of
medication was significantly correlated with the per cent of
days abstinent during the study follow-up period (r = 0.21, 
P < 0.05). In particular, there was a significant positive cor-
relation between the interval from last drinking to the begin-
ning of medication and the per cent of days abstinent during
the first 2 weeks of the study (r = 0.19, P < 0.05). However,
there was no significant correlation during the remainder of the
study period (r = 0.14, P > 0.05). When ANOVAs were con-
ducted using treatment outcomes as a dependent variable,
medication condition as an independent variable and the period
of abstinence prior to treatment as covariate, there was no sig-
nificant effect of medication condition (per cent days abstinent,
F = 0.00, P > 0.05; per cent days without heavy drinking, 
F = 0.07, P > 0.05; mean drinking amount per drinking occasion,
F = 0.64, P > 0.05).
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Fig. 3. Survival curve for no relapse.
Log rank statistics = 0.02, df = 1, P = 0.90 in Kaplan–Meier survival 
analysis. (—) Acamprosate; (---) placebo.
Fig. 2. Survival curve for continuous abstinence.
Log rank statistics = 0.36, df = 1, P = 0.55 in Kaplan–Meier survival 
analysis. (—) Acamprosate; (---) placebo.
Fig. 4. Mean consumption per drinking occasion over time.
Medication group; F(1,102) = 0.34, not significant, time; 
F(1,129) = 49.64, P < 0.05, medication group by time interaction;
F(1,102) = 0.62, not significant in random coefficient regression analysis.
Ac, acamprosate, Pl, placebo.
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Adverse events
During the 8-week study period, 37.5% (27/72) of subjects
receiving acamprosate reported experiencing one or more
symptoms potentially related to the medication. However, the
number of subjects reporting one or more symptoms during
the treatment period did not differ significantly between the
acamprosate- and the placebo-treated group. ‘Constipation/
diarrhoea’ was the most common complaint among the acam-
prosate group (11.1%, 8/72), and this was significantly greater
than in the placebo group (2.9%, 2/70) (c 2 = 2.54, df = 1, P < 0.1
by Fisher’s exact test). ‘Increased appetite’ (11.1%, 8/72),
‘decreased libido’ (8.3%, 6/72), ‘sleeping difficulty’ (8.3%, 6/72),
‘joint or muscle pain’ (8.3%, 6/72) and ‘memory impairment’
(6.9%, 5/72) were common complaints among the acam-
prosate group; however, these were not significantly different
from complaints received from the placebo group.
DISCUSSION
The efficacy of acamprosate in alcohol dependence has been
evaluated by 16 controlled clinical trials conducted across 
11 European countries, which have involved more than 4500
alcohol-dependent patients. Can the positive result obtained
by European studies [except Roussaux et al. (1996) in Belgium
and Chick et al. (2000) in the UK] be replicated in Korean
alcoholics who have a different cultural and genetic background?
The main finding of this study was that acamprosate did 
not show any better treatment outcomes than placebo in the
out-patient treatment of alcohol dependence. Compared with
previous European trials that showed positive findings over a
relatively short treatment duration (3 months), the treatment
efficacy of acamprosate in our study, as represented by the
percentage of subjects who abstained completely, was poorer
[our study, 37%; Lhuintre et al. (1985) in France, 48%; Pelc et al.
(1997) in Belgium, 51%]. It is possible that this difference
may have resulted from the fact that the alcohol dependence of
our sample was too severe to respond to acamprosate.
In general, Koreans are very permissive of heavy drinking
and the behavioural complications resulting from heavy
drinking. For example, ‘heavy drinking’ in the Korean culture
is regarded as an expression of strength and power or an indi-
cation of health or virility. ‘Loss of control’ is also regarded
not as a pathological consequence of drinking, but a common
result of drinking and even one of the purposes of drinking.
The criteria of normal (or social) drinking are dependent not
on the amount or the consequence of drinking, but upon its
purpose. If someone drinks for business purposes or on social
occasions, he is regarded as a social drinker, even though 
he suffers recurrent physical complications of drinking. Mild
to moderate severity of alcohol dependence have been con-
sidered as a sort of personal habit, not as a disease warranting
treatment (Lee et al., 1995, 1997; Room et al., 1996). Repeat-
edly, Koreans tend to restrict their concept of disease to the
physiological consequences of long-term alcohol use, while
Americans accept a definition that is couched largely in social
and behavioural terms (Cho and Faulkner, 1993). It thus ap-
pears that alcohol consumption in Korea is greater, and that
the prevalence of alcoholism by American criteria is higher,
than other countries; however, alcoholics are rarely diagnosed
and treated. Therefore, only patients with a relatively severe
level of alcohol dependence seek treatment.
Actually, 59% of the total sample had previously had treat-
ment and failed. Their mean number of admissions in alcoholism
in-patient programmes was 4.6 ± 6.9, 40% of total subjects
having, in addition, just been treated as in-patients before
entering this trial. Taking into account the higher threshold for
the admission of alcohol-dependent patients into a hospital in
Korea, our sample seems to have a more severe level of alcohol-
ism than even the UK sample (more than 50% had a history of
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Table 2. Treatment effectiveness
Acamprosate Placebo  
Treatment outcomes (n = 72) (n = 70) df t/F P
Primary outcomes
% Subjects who abstained continuously in survival analysis 36.9 31.8 1 0.36a ns
% Subjects who never relapsed in survival analysis 40.0 39.4 1 0.02a ns
% Days abstinent during study period (mean ± SD) 81.2 ± 23.7 78.5 ± 27.8 129 0.60 ns
% Days without heavy drinking during study periodb (mean ± SD) 86.1 ± 20.0 84.9 ± 23.3 129 0.30 ns
Mean drinking amount per drinking occasion during study period (mean ± SD) 7.2 ± 9.8 8.6 ± 9.8 129 0.82 ns
Secondary outcomes
Change of GGT levelc
Baseline (mean ± SD) 87.2 ± 24.3 141.4 ± 23.9
End-point (mean ± SD) 74.0 ± 18.8 98.3 ± 18.5
Medication · time interaction 1 2.714 ns
Change of OCDS total scorec
Baseline (mean ± SD) 19.9 ± 9.6 22.2 ± 11.7
End-point (mean ± SD) 11.5 ± 11.1 14.9 ± 11.2
Medication · time interaction 1 0.316 ns
Change of VASc
Baseline (mean ± SD) 3.2 ± 3.7 3.8 ± 4.0
End-point (mean ± SD) 2.0 ± 2.6 2.7 ± 3.1
Medication · time interaction 1 0.084 ns
aLog rank statistics in Kaplan–Meier survival analysis.
bHeavy drinking is defined by a single day of drinking five or more drinks for men or four or more drinks for women.
cAnalyses of variance with repeated measure from baseline to the end-point carried forward. The effect of interest is the medication group by time interaction.
ns, Not significant.
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treatment failure), which was regarded as being more severe
than previous trials (Chick et al., 2000). The mean ADS score
during baseline, a quantitative index of the severity of alcohol
dependence, of our sample was 22, which also indicates a
substantial level of dependence (Skinner and Horn, 1984).
In addition, the higher unemployment rate (40%) of our
subjects than in previous positive studies (Paille et al., 1995:
21%; Sass et al., 1996: 26%; Tempesta et al., 2000: 32%),
might be another factor that influenced the negative result of
the present study. This possibility is supported by the other
negative studies, which also comprised subjects with high
unemployment (Roussaux et al., 1996: 60%; Chick et al., 2000:
48%).
The comparatively short interval between last drinking and
the first medication may also have contributed to this negative
finding. Compared to previous studies in which all subjects
maintained abstinence for at least 5 days (except Chick et al.,
2000), the mean interval of our sample was merely 3.8 ± 6.4
days and 68.3% of subjects started taking study medication
within 2 days of their last drinking. Actually, as mentioned
above, the period of abstinence prior to treatment was sig-
nificantly correlated with the per cent of days abstinent during
the entire study period (r = 0.21, P < 0.05).
There is a dosage issue of acamprosate, which must also 
be considered. It is common knowledge that genetic factors
are significant determinants of a patient’s response to psycho-
tropic medication, and that dosage requirements and the
potential for toxic reactions might differ among racial and
ethnic groups (Lin et al., 1986). Medication administration
should be also determined by the patient’s environmental 
and cultural background, in addition to the patient’s genetic
predisposition, because these also influence drug response
(Kudzma, 1999). Increasingly, studies have confirmed that
ethnicity affects how people react to drugs. For example,
Korean–American patients achieved significantly lower cloza-
pine concentrations than Caucasians, even after controlling for
differences in daily doses (Matsuda et al., 1996). In contrast to
Korean–American patients, Chinese patients were reported to
have 30–50% higher concentrations than those reported for
Caucasians (Chang et al., 1997). Therefore, a person of Asian
descent is more likely to experience a lack of effectiveness 
or an adverse outcome to pharmacotherapy if the drug hasn’t
been properly adjusted from some Caucasian optimum (Potkin
et al., 1984). Moreover, because a multitude of factors might
interact during the development, diagnosis and treatment of
alcohol dependence, rigorous and carefully designed studies
to optimize dosages are necessary to confirm the efficacy of a
drug treatment for alcohol dependence across ethnic groups.
Actually, a daily schedule of 3 g of acamprosate has recently been
tried in an American acamprosate trial (Mason et al., 1997).
Finally, studies have shown a high prevalence of alcohol
dependence in the Korean population, despite the high fre-
quency of variant aldehyde dehydrogenase allele (ALDH2*2),
known to be a protective factor against alcohol dependence
(Helzer et al., 1990; Lee et al., 1990). This suggests that a
large portion of the alcohol dependence among Koreans might
have been determined socio-culturally, rather than biologically
or genetically. This may be another reason for our subjects’
resistance to treatment with acamprosate.
Several limitations of the present study should be addressed.
First, in the light of a previous finding that the difference in the
rate of abstinence, between acamprosate and placebo, generally
emerged within the first 30–90 days of treatment (Mason,
2001), the 8-week study duration might have been too short to
evaluate the efficacy of acamprosate on the prevention of
relapse. Secondly, the diverse type and dosage of concomitant
psychosocial intervention provided by different centres may
have increased the possibility of a type II error in our study.
Actually, a few centres provided 12-step facilitation or
cognitive behavioural therapy for 60 min at least twice per
week, while other centres provided only a medication
prescription with minimal psychosocial intervention at each
patient’s visit. A number of recent studies have demonstrated
that proper psychosocial intervention can increase the like-
lihood of a significant difference between medication and
placebo in pharmacological trial upon alcohol dependence, by
increasing patient retention, enhancing medication compliance,
and fostering the acquisition of new skills that reinforce the
effects of medication (O’Malley and Carrol, 1996). Therefore,
an increased intensity of psychosocial intervention may
obscure medication effects by improving treatment outcome
in a placebo condition. Conversely, a relatively low intensive
psychosocial approach might even minimize the efficacy of
active medication.
In conclusion, our study did not show any treatment benefit
in terms of outcome of acamprosate treatment. The findings of
this study differ from those of most European clinical trials,
which found that acamprosate helps to maintain abstinence
and prevent relapse in abstinent out-patient alcoholics, over a
3–12-month treatment period following withdrawal. However,
the findings of our study are consistent with those of a Belgium
study by Roussaux et al. (1996) and a UK study by Chick 
et al. (2000). This negative finding might be explained by our
sample’s characteristics (i.e. a more severe form of alcohol
dependence, a lower level of social support, a short interval
between the last drink and the first medication), the dosage
issue of acamprosate, as outlined above, the short study
period, and the variable concomitant psychosocial treatment.
We recommend that optimal treatment dose and concomitant
psychosocial intervention suitable for the treatment of Korean
alcoholics need to be further investigated.
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